ArticleClinical lung cancer2014
Identification of ENO1 as a potential sputum biomarker for early-stage lung cancer by shotgun proteomics.
Article in Clinical lung cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 51 citations in OpenAlex.
- Developing technologies and areas of interest in lung cancer screening adjuncts.Journal of thoracic disease · 2024Review
- Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice.Proteomes · 2023Review
- Review
- diaPASEF Proteomics and Feature Selection for the Description of Sputum Proteome Profiles in a Cohort of Different Subtypes of Lung Cancer Patients and Controls.International journal of molecular sciences · 2022Article
- Proteomic Analysis of Human Sputum for the Diagnosis of Lung Disorders: Where Are We Today?International journal of molecular sciences · 2022Review
- [Role and Significance of Bioactive Substances in Sputum in the Diagnosis of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- Proteomics, Personalized Medicine and Cancer.Cancers · 2021Review
- High-Throughput Detection of Multiple miRNAs and Methylated DNA by Droplet Digital PCR.Journal of personalized medicine · 2021Article
- Microbiota Biomarkers for Lung Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- Characterizing heterogeneity of non-small cell lung tumour microenvironment to identify signature prognostic genes.Journal of cellular and molecular medicine · 2020Article
- A Non-Coding RNA Landscape of Bronchial Epitheliums of Lung Cancer Patients.Biomedicines · 2020Article
- MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC).Thoracic cancer · 2020Article
- The circ-AMOTL1/ENO1 Axis Implicated in the Tumorigenesis of OLP-Associated Oral Squamous Cell Carcinoma.Cancer management and research · 2020Article
- Enolase 1 Correlated With Cancer Progression and Immune-Infiltrating in Multiple Cancer Types: A Pan-Cancer Analysis.Frontiers in oncology · 2020Article
- Leukotriene AFrontiers in immunology · 2020Article
- Sputum long non-coding RNA biomarkers for diagnosis of lung cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- Simultaneous sequencing of coding and noncoding RNA reveals a human transcriptome dominated by a small number of highly expressed noncoding genes.RNA (New York, N.Y.) · 2018Article
- Integrating Circulating Immunological and Sputum Biomarkers for the Early Detection of Lung Cancer.Biomarkers in cancer · 2018Article
- A prediction model for distinguishing lung squamous cell carcinoma from adenocarcinoma.Oncotarget · 2017Article
- Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.Theranostics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundLung cancer is the leading cancer killer. Early detection will reduce the related deaths. The objective of this study was to identify potential biomarkers for early-stage lung cancer in sputum supernatant. MATERIALS AND
methodsUsing shotgun proteomics, we detected changes in protein profiles that were associated with lung cancer by analyzing sputum supernatants from 6 patients with early-stage lung cancer and 5 cancer-free controls. Using western blotting, we validated the proteomic results in 22 lung cancer cases and 22 controls. Using enzyme-linked immunosorbent assay (ELISA), we evaluated the diagnostic performance of the biomarker candidates in an independent set of 35 cases and 36 controls.
resultsProteomics identified 8 biomarker candidates for lung cancer. Western blotting validation of the candidates showed that enolase 1 (ENO1) displayed a higher expression level in patients with cancer than in cancer-free individuals (P = .015). ELISA revealed that the assessment of ENO1 expression in sputum supernatant had 58.33% sensitivity and 80.00% specificity in distinguishing patients with stage I lung cancer from cancer-free individuals.
conclusionThe analysis of protein biomarkers in sputum may provide a potential approach for the early detection of lung cancer. Future validation of all the candidates defined by shotgun proteomics in a large cohort study may help develop additional biomarkers that can be added to ENO1 to provide more diagnostic efficacy for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.